Semaglutide Plus Cagrilintide Reduced Blood Sugar, Weight in T2D

(MedPage Today) -- SAN DIEGO -- Treatment with semaglutide 2.4 mg co-administered with the investigational long-acting amylin analogue cagrilintide (known together as CagriSema) led to improvements in glycemic control and reductions in body weight...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
More News: Primary Care | Sugar